Biovica Receives €682,000 in EU Funding

UPPSALA, Sweden, June 9, 2015 /PRNewswire/ --

The European Commission has selected Biovica as one of the companies to receive support in the Horizon 2020 phase 2 program. Biovica's project entitled "Clinical validation of the DiviTum assay in two high profile clinical studies in Europe" is supported with € 682,000 and is carried out in collaboration with a European cancer study group and Karolinska Institutet.

The European Commission received 614 proposals (by the cut-off date of March 18, 2015) but only 42 have been selected for funding.

"We are very pleased that our study program in collaboration with our distinguished partners is supported in phase 2 of the Horizon 2020 program. I am especially pleased that we received an excellent evaluation score and that the Commission believes that our project will give a high impact. With this approval and substantial financial support we get the  acknowledgement to continue to demonstrate the unique values and potential that DiviTum™  can bring to cancer patients," says Anders Rylander, CEO Biovica.

The project is focusing on clinical studies where DiviTum™ will be evaluated as a companion tool to evaluate efficacy of a very promising type of new cancer drug recently approved. The goal of the project is to bring further evidence of DiviTum™ as a predictive and monitoring biomarker in solid tumours, enabling better clinical decisions for cancer therapy and drug development, resulting in a more optimal treatment for patients.

Facts about Biovica and DiviTum™ 

Biovica is a biotech company focused on improving diagnostics, providing better predictive information and monitoring of patients with cancer. Biovica has developed a simple blood test, DiviTum™, a highly sensitive assay for measuring cell proliferation rate. DiviTum™ measures an enzyme with a key function in cell division and the rate in which tumour cells grow. DiviTum™ has demonstrated unique values in cancer, predicting therapy efficacy and monitoring the status of the disease and treatment. Biovica is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE labelled and MPA registered. In the US DiviTum™ is available for research use only. See also http://www.biovica.com.

Facts about the Horizon 2020 SME programme

http://ec.europa.eu/research/participants/portal/desktop/en/funding/sme_participation.html

For more information:

Anders Rylander, CEO Biovica
Mobile phone: +46-(0)761-61-21-90 e-mail: anders.rylander@biovica.com

EU Horizon 2020:
RTD-RESEARCH-PRESS@ec.europa.eu

SOURCE Biovica